摘要
评估双阶段的功效的目的在 preliminarily 在 bronchogenic 癌估计没有外科的治疗反应对比提高材料的计算断层摄影术(CT ) 。有在没有外科的治疗以后的 bronchogenic 癌的 52 个病人经历了双阶段的方法对比提高材料的计算断层摄影术。在非离子的对比材料经由赌注被管理以后，二螺线 CT 扫描分别地在 25 和 90 秒点被获得以由使用一个汽车注射者的 4 mL/s 的率的肘的静脉。每扫描上的 Precontrast 和柱子对比变细被记录，山峰高度是计算的。改进模式在在对比媒介的注射以后在 25 和 90 秒点获得的图象上被评估。结果 Precontrast 变细，在 25 和 90 秒点的柱子对比变细是 42.20 ± 7.43 胡， 57.35 ± 10.09 胡和 71.85 ± 12.45 胡分别地。在 precontrast 变细的统计上重要的差别都没在我们在治疗前在情况中被获得的旧学习(吝啬的 precontrast 变细 40.70 胡) 在学习和结果在我们的结果之间被发现(t = 1.455， P = 0.152 】
0.05 ) 。在没有外科的治疗以后的 bronchogenic 癌的山峰高度(29.46 ± 10.85 胡) 是比在在我们的旧学习获得的治疗前的 bronchogenic 癌的显著地低的(吝啬的山峰高度 35.79 胡；t = 4.206， P = 0.001 【
0.05 ) 。52 个盒子中的 32 个在 90 秒点显示出同类的改进。32 个盒子，与不同类的改进有 21， 7 与不同类的改进， 2 与中央改进并且 2 与在 25 秒点的外部改进。在没有外科的处理以后的结论 Bronchogenic 癌在对比材料的管理以后显示出渐渐的增加到山峰高度。山峰高度能反映 bronchogenic 癌的血供应并且可能是为在 bronchogenic 癌的没有外科的治疗反应的评估的索引。
Objective： To evaluate the efficacy of double-phase contrast material-enhanced computed tomography （CT） in assessing no-surgical treatment response in bronchogenic carcinoma preliminarily. Methods： 52 patients with bronchogenic carcinoma after no-surgical treatment underwent double-phase contrast material-enhanced computed tomography. Two spiral CT scans were obtained at 25 and 90 seconds respectively after nonionic contrast material was administrated via the antecubital vein at a rate of 4 mUs by using an autoinjector. Precontrast and postcontrast attenuation on every scan was recorded and peak height was calculated. Enhancement pattern was evaluated on the images obtained at 25 and 90 seconds after injection of contrast medium. Results： Precontrast attenuation, postcontrast attenuation at 25 and 90 seconds were 42.20 ± 7.43 Hu, 57.35 ± 10.09 Hu and 71.85 ±12.45 Hu, respectively. No statistically significant difference in precontrast attenuation was found between our results in the study and the results in our old study （mean precontrast attenuation 40.70 Hu） which was obtained in cases before therapy （t = 1.455, P = 0.152 〉 0.05）. Peak height of bronchogenic carcinoma after no-surgical treatment （29.46 ±10.85 Hu） were significantly lower than that of bronchogenic carcinoma before therapy obtained in our old study （mean peak height 35.79 Hu; t = 4.206, P = 0.001 〈 0.05）. 32 of 52 cases showed homogeneous enhancement at 90 seconds. Of the 32 cases, there were 21 with inhomogeneous enhancement, 7 with inhomogeneous enhancement, 2 with central enhancement and 2 with peripheral enhancement at 25 seconds. Conclusion： Bronchogenic carcinoma after no-surgical treatment shows a gradual increase to the peak height after administration of contrast material. Peak heights can reflect the blood supply of bronchogenic carcinoma and might be index for evaluation of no-surgical treatment response in bronchogenic carcinoma.
